Overview
Italy filtration solutions firm's FY 2025 revenue up 2% at constant FX, slight miss vs estimates
Adjusted EBITDA up 3%, slightly beating analyst expectations
Adjusted EBIT exceeded analyst estimates
Outlook
GVS expects low single-digit revenue growth at constant FX in FY2026 vs. FY2025
Company sees adjusted EBITDA margin expansion of 20–50 bps in FY2026 vs. FY2025
GVS expects leverage ratio of about 1.8x as of December 31, 2026
Result Drivers
HEALTHCARE & LIFE SCIENCES - Division revenue up 1.5% at constant FX, supported by Haemonetics' Whole Blood acquisition; US hemodialysis sales declined
SAFETY DIVISION GROWTH - Safety division revenue up 11.9% at constant FX
ENERGY & MOBILITY DECLINE - Energy & Mobility division revenue down 7.5% at constant FX, weighing on overall growth
Company press release: ID:nBIA8zsGgG
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | Slight Miss* | EUR 424.70 mln | EUR 427.88 mln (5 Analysts) |
FY Adjusted EBITDA | Slight Beat* | EUR 107 mln | EUR 105.94 mln (5 Analysts) |
FY Adjusted EBIT | Beat | EUR 75.80 mln | EUR 72.50 mln (5 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for GVS SpA is €5.30, about 41.3% above its March 25 closing price of €3.75
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)